Home/Filings/4/0001209191-23-020677
4//SEC Filing

Dunn Michael J. 4

Accession 0001209191-23-020677

CIK 0001534133other

Filed

Mar 21, 8:00 PM ET

Accepted

Mar 22, 8:47 PM ET

Size

31.3 KB

Accession

0001209191-23-020677

Insider Transaction Report

Form 4
Period: 2023-03-20
Dunn Michael J.
President and COO
Transactions
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+11,76111,761 total
    Exercise: $1.39Exp: 2024-10-01Common Stock (11,761 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+8,6408,640 total
    Exercise: $2.44Exp: 2029-04-24Common Stock (8,640 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+7,9157,915 total
    Exercise: $7.99Exp: 2031-04-27Common Stock (7,915 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+22,77722,777 total
    Exercise: $2.44Exp: 2028-08-01Common Stock (22,777 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+23,58923,589 total
    Exercise: $6.60Exp: 2030-06-29Common Stock (23,589 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+13,14713,147 total
    Exercise: $7.99Exp: 2031-04-27Common Stock (13,147 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+1,3231,323 total
    Exercise: $10.42Exp: 2032-08-30Common Stock (1,323 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+847847 total
    Exercise: $17.34Exp: 2023-03-19Common Stock (847 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+7,9157,915 total
    Exercise: $7.99Exp: 2031-06-30Common Stock (7,915 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+1,9541,954 total
    Exercise: $10.42Exp: 2032-08-30Common Stock (1,954 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-03-20+24,74724,747 total
    Exercise: $17.34Exp: 2033-03-19Common Stock (24,747 underlying)
Footnotes (16)
  • [F1]Immediately exercisable.
  • [F10]Received in exchange for a stock option to acquire 274,848 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F11]Received in exchange for a stock option to acquire 456,522 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F12]Received in exchange for a stock option to acquire 45,955 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F13]Received in exchange for a stock option to acquire 67,873 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F14]Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
  • [F15]Received in exchange for a stock option to acquire 859,280 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F16]Received in exchange for a stock option to acquire 29,420 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F2]Received in exchange for a stock option to acquire 408,402 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.
  • [F3]Received in exchange for a stock option to acquire 790,880 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F4]Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.
  • [F5]25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.
  • [F6]Received in exchange for a stock option to acquire 300,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F7]25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.
  • [F8]Received in exchange for a stock option to acquire 819,064 shares of common stock of CalciMedica pursuant to the Merger Agreement.
  • [F9]Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

Issuer

CalciMedica, Inc. /DE/

CIK 0001534133

Entity typeother

Related Parties

1
  • filerCIK 0001968792

Filing Metadata

Form type
4
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 8:47 PM ET
Size
31.3 KB